Moderna, Inc. (MRNA) Balance Sheet

The shrinking balance sheet reflects cumulative losses and inventory write-downs, with retained earnings dropping from $12.4B to $5.1B over the period. This trajectory suggests the company is consuming its capital base to fund operations and pipeline development, with no near-term reversal apparent. The pace of asset decline appears to be accelerating, as the $0.5B drop in 2026Q2 alone indicates continued pressure.

The increase in debt appears strategic, providing a buffer as operating cash flow remains negative, but the rising leverage ratio signals a gradual shift from a fortress balance sheet to one under strain. With cash and equivalents at $1.7B versus $1.3B in debt, the net cash position is thin, and investors should monitor whether further borrowing becomes necessary to fund the pipeline. The debt level is still modest relative to assets, but the trend warrants attention.

The substantial PP&E base, built for pandemic-era volumes, appears underutilized given the sharp revenue decline, and management's 'right-sizing' efforts have led to impairment charges. The low goodwill suggests the company's value lies in its internal platform and pipeline, not acquisitions, but the fixed asset base may continue to drag returns. As revenue contracts, the asset intensity of the business model becomes a liability, pressuring margins and ROIC.

The equity base is being eroded by persistent losses, with no dividends or significant buybacks to support shareholders. SBC, while non-cash, dilutes existing holders and adds to the cost structure, further pressuring equity quality. The decline in retained earnings suggests the company is prioritizing pipeline investment over balance sheet preservation, a deliberate but risky strategy.

The current ratio remains above 2, but the trend is concerning as cash burn persists and revenue declines. With operating cash flow averaging -$0.8B per quarter, the current cash position provides roughly two quarters of runway, assuming no additional revenue or financing. The liquidity buffer appears adequate for the near term but is deteriorating, and investors should monitor whether the company can access capital markets if needed.

The shrinking deferred revenue balance suggests that customers are committing less upfront, reflecting the transition from government contracts to a seasonal commercial market. This trend implies lower forward revenue visibility and may indicate weaker demand for the COVID franchise. The modest $442M balance provides limited cushion against the ongoing revenue decline, reinforcing concerns about top-line stability.